Regorafenib Plus Vincristine and Irinotecan in Pediatric Patients With Recurrent/Refractory Solid Tumors: An Innovative Therapies for Children With Cancer Study

CONCLUSIONS: Regorafenib can be combined sequentially with standard dose VI in pediatric patients with relapsed/refractory solid tumors with appropriate dose modifications. Clinical activity was observed in patients with RMS and EWS (clinicaltrials.gov NCT02085148).PMID:37606641 | DOI:10.1158/1078-0432.CCR-23-0257

Source: Cancer Control - August 22, 2023 Category: Cancer & Oncology Authors: Michela Casanova Francisco Bautista Quentin Campbell Hewson Guy Makin Lynley V Marshall Arnauld C Verschuur Adela Ca ñete Nieto Nadege Corradini Bart A Ploeger Barbara J Brennan Udo Mueller Hong Zebger Gong John W Chung Birgit Geoerger Source Type: research